Drug Profile


Alternative Names: Canef; Cranoc; Digaril; Fractal; Hovalin; Lescol; Lescol XL; Lipaxan; Lochol; Lymetel; Primesin; SRI 62320; Vastin; XU 62320

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer AbbVie; Almirall S.A.; AstraZeneca; Bayer; Berenguer-Infale; Italfarmaco; Mitsubishi Tanabe Pharma Corporation; Novartis; Pierre Fabre; Reliant Pharmaceuticals; Sanofi; sanofi-aventis; Solvay
  • Class Antihyperlipidaemics; Indoles; Monounsaturated fatty acids
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemias; Hypertriglyceridaemia
  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 18 Sep 2015 First Generic equivalent available in USA for Hyperlipidaemia
  • 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top